GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
N

NaviFUS 6872.TWO · TWD

Health Care · Taipei Exchange · 🇹🇼 Taiwan

Compare

17.60

+3.23%

Close of 9 Nov 2026, in TWD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About NaviFUS

Its shares trade on Taipei Exchange under the ticker 6872.TWO. It has been listed since 22 June 2022. In the fiscal year to 31 December 2025, it reported revenue of TWD 10.5m and a net loss of TWD 148.5m. At that date it held total assets of TWD 636.0m and shareholders' equity of TWD 555.6m.

NaviFUS Corp. operates as a medical device company. The company is headquartered in Taipei City, Taipei. The company went IPO on 2022-06-22. The firm focuses on the development of two core technology platforms: focused ultrasound systems and therapeutic guidance tracking systems. The firm focuses on the development of medical systems for recurrent brain tumors and Alzheimer's disease.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Health Care Equipment & Supplies
Listed since
22 Jun 2022
Website
navifus.com ↗

Leadership

Pay as last reported

  • Jen ChenChairman of the Board
  • Ziyun ZhouFinance Manager, Corporate Governance Officer, since 2024
  • Chen-Yu LungActing Chief Operating Officer, General Manager, Director, since 2024
  • Gui-biao ChenDirector
  • Chia-Chen ChuDirector
  • Hao-Li LiuDirector
  • Chia-Lin ChenIndependent Director
  • Jia-Jin ChenIndependent Director
  • Hann-Tarn JenIndependent Director
  • Hsiou-chi LiouIndependent Director

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • NaviFUS Corp. is a medical device company with headquarters in Taipei City.
  • The company has two core technology platforms: focused ultrasound systems and therapeutic guidance tracking systems.
  • NaviFUS Corp. focuses on medical systems for recurrent brain tumors and Alzheimer's disease.

Weaknesses

  • The company's focus on specific medical conditions may limit market reach.
  • The firm's IPO occurred in 2022, indicating a relatively new market presence.
  • The company operates in a highly regulated health care sector, increasing operational complexity.

Opportunities

  • Growing demand for innovative medical treatments for brain tumors and Alzheimer's disease.
  • Potential expansion into new markets for focused ultrasound technology.
  • Advancements in medical technology could enhance the company's core platforms.

Threats

  • Regulatory challenges in the health care sector may hinder product development.
  • Competition from established medical device companies could impact market share.
  • Economic downturns might reduce investment in health care innovation.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.